Eagle Asset Management’s United Therapeutics UTHR Stock Holding History

Eagle Asset Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,408	Closed	-$2.11M	–	576
2023 Q1	$2.11M	Sell	9,408 -6	-0.1%	-$1.48K	0.01%	436
2022 Q4	$2.57M	Sell	9,414 -164	-2%	-$41.4K	0.02%	405
2022 Q3	$2M	Sell	9,578 -56	-0.6%	-$12.5K	0.01%	432
2022 Q2	$2.27M	Buy	+9,634	New	+$1.96M	0.01%	429
2014 Q2	–	Sell	-645,763	Closed	-$60.7M	–	668
2014 Q1	$60.7M	Sell	645,763 -1,346,206	-68%	-$138M	0.33%	93
2013 Q4	$225M	Buy	1,991,969 +133,217	+7%	+$12M	1.27%	2
2013 Q3	$146M	Buy	1,858,752 +89,576	+5%	+$6.55M	0.72%	22
2013 Q2	$116M	Buy	+1,769,176	New	+$114M	0.77%	18

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eagle Asset Management's UTHR Position: Q2 2023 in Review

Eagle Asset Management sold out of United Therapeutics (UTHR) in Q2 2023, closing a stake of 9,408 shares — an estimated $2.11M sold.

Eagle Asset Management first reported a position in UTHR in Q2 2013 and held it in 8 quarters. The position peaked at $225M in Q4 2013. 475 funds tracked by Wall St. Rank hold UTHR as of Q2 2023.

Eagle Asset Management reported no remaining United Therapeutics position as of Q2 2023 after selling out during the quarter.
Eagle Asset Management sold 9,408 United Therapeutics shares in Q2 2023, an estimated $2.11M.
Eagle Asset Management first reported a position in United Therapeutics in Q2 2013 and held it in 8 quarters.
Eagle Asset Management's United Therapeutics position peaked at $225M in Q4 2013.
475 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2023.

Based on Eagle Asset Management's 13F filing for Q2 2023, filed 9 Aug 2023.